AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35670658 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery phase in hyperglycemia (20 mmol/L)
Number of subjects: 24
Study 35670658 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery phase in euglycemia (5.0-8.0 mmol/L)
Number of subjects: 24
Study 35670658 — intervention group
Group type: COMPARATOR
Intervention: Comparison of recovery phases: hyperglycemia vs euglycemia
Number of subjects: 24
Study 32064716 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation (LAI) with 2% sodium hypochlorite (NaOCl)
Number of subjects: 240
Study 32064716 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-activated irrigation (LAI)
Number of subjects: 240
Study 32064716 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle irrigation (CNI)
Number of subjects: 240
Study 36215226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose vitamin D (800 IU/day)
Number of subjects: 6200
Study 36215226 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose vitamin D (3200 IU/day)
Number of subjects: 6200
Study 36215226 — intervention group
Group type: COMPARATOR
Intervention: No offer of testing or supplementation
Number of subjects: 6200
Study 33020803 — intervention group
Group type: EXPERIMENTAL
Intervention: Melody condition
Number of subjects: 53
Study 33020803 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmony condition
Number of subjects: 53
Study 33020803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Attention Awareness Scale scores
Number of subjects: 53
Study 33109638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (mentoring approach)
Number of subjects: 420
Study 33109638 — intervention group
Group type: COMPARATOR
Intervention: Comparison (standard dissemination via circular)
Number of subjects: 420
Study 35166230 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic partial tubal resection with end‐to‐end anastomosis (observation group)
Number of subjects: 451
Study 35166230 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic fenestration (control group)
Number of subjects: 451
Study 33797089 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO/Fibre diet
Number of subjects: 45
Study 33797089 — intervention group
Group type: COMPARATOR
Intervention: MUFA diet
Number of subjects: 45
Study 33797089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CHO/Fibre and MUFA groups
Number of subjects: 45
Study 35738688 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined a consensual kiss with a moral man
Number of subjects: 148
Study 35738688 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined a consensual kiss with an immoral man
Number of subjects: 148
Study 35738688 — intervention group
Group type: EXPERIMENTAL
Intervention: Received a non-consensual kiss from a moral man
Number of subjects: 148
Study 35738688 — intervention group
Group type: EXPERIMENTAL
Intervention: Received a non-consensual kiss from an immoral man
Number of subjects: 148
Study 35738688 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined a non-consensual kiss
Number of subjects: 148
Study 34559058 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-way SMS text messaging program (4 messages per week for 6 months)
Number of subjects: 879
Study 34559058 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care only)
Number of subjects: 879
Study 35390529 — intervention group
Group type: EXPERIMENTAL
Intervention: haplo-BMT
Number of subjects: 367
Study 35390529 — intervention group
Group type: COMPARATOR
Intervention: dUCB
Number of subjects: 367
Study 33753690 — intervention group
Group type: EXPERIMENTAL
Intervention: Online course
Number of subjects: 20
Study 33753690 — intervention group
Group type: COMPARATOR
Intervention: Classroom sessions
Number of subjects: 20
Study 32363614 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Sufficient Balance (MSB) method
Number of subjects: 0
Study 32363614 — intervention group
Group type: COMPARATOR
Intervention: Minimization method
Number of subjects: 0
Study 32363614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 0
Study 35333702 — intervention group
Group type: EXPERIMENTAL
Intervention: TyphiBEVTM
Number of subjects: 622
Study 35333702 — intervention group
Group type: COMPARATOR
Intervention: Typbar-TCV
Number of subjects: 622
Study 35026070 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized prevention recommendations and lifestyle interventions
Number of subjects: 3868
Study 35183242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 0
Study 35183242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 35183242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol
Number of subjects: 0
Study 35183242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33473162 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial exclusion (5 min in experiment 1; 10 min in experiment 2)
Number of subjects: 162
Study 33473162 — intervention group
Group type: COMPARATOR
Intervention: Inclusion (2 min in experiment 1; 2 min in experiment 2)
Number of subjects: 162
Study 33473162 — intervention group
Group type: COMPARATOR
Intervention: Control condition (12 min inclusion only in experiment 2)
Number of subjects: 162
Study 32838773 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking Time intervention (telephone-based support, including preliminary talk, information booklet, six structured meetings, and written self-evaluation)
Number of subjects: 38
Study 32838773 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual individual self-organized care)
Number of subjects: 38
Study 32838773 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (not specified)
Number of subjects: 38
Study 35193803 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 0.5 g/L tranexamic acid (TXA)
Number of subjects: 40
Study 35193803 — intervention group
Group type: COMPARATOR
Intervention: Control group with 0.9% sodium chloride
Number of subjects: 40
Study 33637543 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to participate in a cancer surveillance RCT
Number of subjects: 130
Study 33637543 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for participation
Number of subjects: 130
Study 33637543 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for declining participation
Number of subjects: 130
Study 33637543 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of cancer research
Number of subjects: 130
Study 36457073 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week multifaceted lifestyle intervention including nutrition and physical activity education, produce harvesting, cooking demonstrations, nutrition counseling, and kinetic activities.
Number of subjects: 0
Study 36457073 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 33421230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrosomial iron (SI) 28 mg daily for 3 months
Number of subjects: 25
Study 33421230 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched HFrEF patients)
Number of subjects: 25
Study 34536949 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (Abi + P) + ADT
Number of subjects: 200
Study 34536949 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 200
Study 35392847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful with Your Baby intervention
Number of subjects: 17
Study 32621877 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI combined with clinical prognostic factors (CPF)
Number of subjects: 85
Study 32621877 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-parametric MRI combined with CPF
Number of subjects: 85
Study 32621877 — intervention group
Group type: COMPARATOR
Intervention: Individual MRI parameters (D, Ktrans, Ve)
Number of subjects: 85
Study 32621877 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of cancer
Number of subjects: 85
Study 32621877 — intervention group
Group type: EXPERIMENTAL
Intervention: D, Ktrans, Ve
Number of subjects: 85
Study 33068669 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right DLPFC at 2 mA for 20 min
Number of subjects: 21
Study 33068669 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS over the right DLPFC
Number of subjects: 21
Study 32359056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer warning labels applied to alcohol containers for 1 month at the intervention site.
Number of subjects: 2049
Study 34636216 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe irrigation
Number of subjects: 72
Study 34636216 — intervention group
Group type: EXPERIMENTAL
Intervention: Tornado Brush
Number of subjects: 72
Study 34636216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated irrigation
Number of subjects: 72
Study 34636216 — intervention group
Group type: EXPERIMENTAL
Intervention: MM‐Seal
Number of subjects: 72
Study 32928122 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier box (BB)
Number of subjects: 78
Study 32928122 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) without barrier box
Number of subjects: 78
Study 33637605 — intervention group
Group type: EXPERIMENTAL
Intervention: D-allulose 7.5 g
Number of subjects: 30
Study 33637605 — intervention group
Group type: EXPERIMENTAL
Intervention: D-allulose 10 g
Number of subjects: 30
Study 32938620 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort A)
Number of subjects: 71
Study 32938620 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort B1)
Number of subjects: 71
Study 32938620 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 200 mg daily for 2 weeks and 1 week off plus trastuzumab (cohort B2)
Number of subjects: 71
Study 32938620 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib in combination with trastuzumab
Number of subjects: 71
Study 34694437 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BCP)
Number of subjects: 27
Study 34694437 — intervention group
Group type: EXPERIMENTAL
Intervention: delNido cardioplegia (dNCP)
Number of subjects: 27
Study 34694437 — intervention group
Group type: COMPARATOR
Intervention: Custodiol cardioplegia (CCP)
Number of subjects: 27
Study 34349503 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of regorafenib (40 mg)
Number of subjects: 66
Study 34349503 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of regorafenib (Stivarga®, 40 mg)
Number of subjects: 66
Study 34349503 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations of regorafenib (40 mg)
Number of subjects: 66
Study 32941498 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-grade wearable (Huami Arc) with a threshold of 10 units
Number of subjects: 41
Study 32941498 — intervention group
Group type: COMPARATOR
Intervention: Research-grade actigraph (Philips Actiwatch Spectrum)
Number of subjects: 41
Study 35864302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 20 mg and Dimenhydrinate 40 mg
Number of subjects: 795
Study 35864302 — intervention group
Group type: COMPARATOR
Intervention: Cinnarizine 20 mg
Number of subjects: 795
Study 35864302 — intervention group
Group type: COMPARATOR
Intervention: Betahistine dimesylate 12 mg
Number of subjects: 795
Study 35864302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine/Dimenhydrinate group
Number of subjects: 795
Study 35864302 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 795
Study 33784411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INCS) - triamcinolone acetonide (220 µg)
Number of subjects: 10
Study 34915109 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum ACE2 activity
Number of subjects: 228
Study 34915109 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ACE2 activity
Number of subjects: 228
Study 33531881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified periprocedural physiotherapy including inspiratory muscle training
Number of subjects: 108
Study 33531881 — intervention group
Group type: COMPARATOR
Intervention: Standard postprocedural physiotherapy (control group)
Number of subjects: 108
Study 32810089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent kangaroo mother care for seven days
Number of subjects: 140
Study 32810089 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 140
Study 32810089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent kangaroo mother care
Number of subjects: 140
Study 32810089 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care therapy
Number of subjects: 140
Study 34654905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound renal denervation
Number of subjects: 143
Study 34654905 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 143
Study 32612308 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin for 3 days
Number of subjects: 4002
Study 32612308 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 4002
Study 32612308 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 4002
Study 32612308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4002
Study 36417057 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg EOD
Number of subjects: 695
Study 36417057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study 36417057 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg EOD (after switching from placebo)
Number of subjects: 695
Study 34137551 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Trocar Insertion (DTI)
Number of subjects: 400
Study 34137551 — intervention group
Group type: COMPARATOR
Intervention: Veress Needle Insertion (VNI)
Number of subjects: 400
Study 32991399 — intervention group
Group type: EXPERIMENTAL
Intervention: Light vegetarian diet (LVD)
Number of subjects: 90
Study 32991399 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingjiang Tiaochang Recipe (QJTCR)
Number of subjects: 90
Study 32991399 — intervention group
Group type: COMPARATOR
Intervention: Placebo + diet
Number of subjects: 90
Study 32991399 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine + diet
Number of subjects: 90
Study 36081341 — intervention group
Group type: COMPARATOR
Intervention: Typical museum website (Ash)
Number of subjects: 463
Study 36081341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (WoB and Ash)
Number of subjects: 463
Study 33972795 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy
Number of subjects: 90
Study 33972795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32347777 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3) administered intradermally or intramuscularly
Number of subjects: 89
Study 34871580 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.62% transdermal testosterone gel
Number of subjects: 6000
Study 34871580 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo gel
Number of subjects: 6000
Study 33829679 — intervention group
Group type: EXPERIMENTAL
Intervention: VL10%
Number of subjects: 33
Study 33829679 — intervention group
Group type: EXPERIMENTAL
Intervention: VL30%
Number of subjects: 33
Study 33829679 — intervention group
Group type: EXPERIMENTAL
Intervention: VL45%
Number of subjects: 33
Study 35791734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (ω‐3 fatty acids)
Number of subjects: 0
Study 35791734 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (ω‐6 fatty acids)
Number of subjects: 0
Study 35791734 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (ω‐6 fatty acids) after washout
Number of subjects: 0
Study 32681263 — intervention group
Group type: EXPERIMENTAL
Intervention: Households experiencing moderate hunger
Number of subjects: 525
Study 32681263 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate feeding practices
Number of subjects: 525
Study 32681263 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate household hunger
Number of subjects: 525
Study 32681263 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunting
Number of subjects: 525
Study 32681263 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 525
Study 32681263 — intervention group
Group type: EXPERIMENTAL
Intervention: Wasting
Number of subjects: 525
Study 32681263 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite index of anthropometric failure (CIAF)
Number of subjects: 525
Study 35543281 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF 60 µg with Al(OH)3
Number of subjects: 0
Study 35543281 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF 60 µg with CpG/Al(OH)3
Number of subjects: 0
Study 35543281 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF 120 µg with Al(OH)3
Number of subjects: 0
Study 35543281 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF 120 µg with CpG/Al(OH)3
Number of subjects: 0
Study 35543281 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF 240 µg with Al(OH)3
Number of subjects: 0
Study 35543281 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF 240 µg with CpG/Al(OH)3
Number of subjects: 0
Study 35543281 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF 240 µg unadjuvanted
Number of subjects: 0
Study 35543281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35543281 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF 240 µg with CpG/Al(OH)3 (month 0,2 cohort)
Number of subjects: 0
Study 35543281 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose seasonal inactivated influenza vaccine (SIIV)
Number of subjects: 0
Study 35543281 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF formulations
Number of subjects: 0
Study 33148479 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 mg plus Tamoxifen 20 mg (A+T)
Number of subjects: 0
Study 33148479 — intervention group
Group type: COMPARATOR
Intervention: Abemaciclib 200 mg plus prophylactic loperamide (A-200)
Number of subjects: 0
Study 33148479 — intervention group
Group type: COMPARATOR
Intervention: Abemaciclib 150 mg every 12 hours (A-150)
Number of subjects: 0
Study 33157186 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential radiofrequency ablation
Number of subjects: 197
Study 36219407 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg daily plus Oxycodone 10 mg
Number of subjects: 25
Study 36219407 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (100 mg to 400 mg) plus Oxycodone 10 mg
Number of subjects: 25
Study 36219407 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg daily
Number of subjects: 25
Study 36219407 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (100 mg to 400 mg)
Number of subjects: 25
Study 36219407 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Oxycodone 10 mg
Number of subjects: 25
Study 34492561 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatigue induced using the Stroop colour‐word task
Number of subjects: 48
Study 34492561 — intervention group
Group type: COMPARATOR
Intervention: Control group (not mentally fatigued)
Number of subjects: 48
Study 34492561 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatigue
Number of subjects: 48
Study 33966009 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat Jump Force-Velocity Profile
Number of subjects: 18
Study 33966009 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat Jump Load-Velocity Profile
Number of subjects: 18
Study 33966009 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-Velocity Profiles created with peak force and relative peak force
Number of subjects: 18
Study 33966009 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-Velocity Profiles created with mean and relative mean forces
Number of subjects: 18
Study 32183908 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive deviance intervention for promoting dual-method use
Number of subjects: 960
Study 32183908 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard approach)
Number of subjects: 960
Study 33941921 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with FGFR inhibitors
Number of subjects: 135
Study 33941921 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with PARP inhibitors
Number of subjects: 135
Study 33941921 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with TORC1/2 inhibitors
Number of subjects: 135
Study 33941921 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab monotherapy
Number of subjects: 135
Study 33941921 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker analysis
Number of subjects: 135
Study 32172602 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 50
Study 32172602 — intervention group
Group type: COMPARATOR
Intervention: Control (moderate continuous training)
Number of subjects: 50
Study 35499452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained pre-manipulative thrust C0-1
Number of subjects: 19
Study 35499452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained cervical end of range rotation
Number of subjects: 19
Study 35499452 — intervention group
Group type: COMPARATOR
Intervention: Sham position
Number of subjects: 19
Study 32469260 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot extract (600 mg in capsule)
Number of subjects: 12
Study 32469260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (600 mg starch in capsule)
Number of subjects: 12
Study 32173607 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) 30 L/min
Number of subjects: 10
Study 32173607 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) 60 L/min
Number of subjects: 10
Study 35728808 — intervention group
Group type: EXPERIMENTAL
Intervention: VL15
Number of subjects: 50
Study 35728808 — intervention group
Group type: EXPERIMENTAL
Intervention: VL25
Number of subjects: 50
Study 35728808 — intervention group
Group type: EXPERIMENTAL
Intervention: VL50
Number of subjects: 50